Clinical Scorecard: Investigational Drug Shows Potential in Phase 3 Obesity Trial

At a Glance

Key Highlights

• Survodutide led to greater weight loss compared to placebo over 76 weeks.
• 73% of patients on 3.6 mg and 72% on 6.0 mg achieved at least 5% weight loss.
• Significant reductions in waist circumference and fat volume were observed.
• Adverse gastrointestinal events were the primary safety concern.
• No mortality was reported during the trial.

Guideline-Based Recommendations

Diagnosis

• Patients must have a BMI of at least 30 or at least 27 with obesity-related complications.

Management

• Survodutide titrated to 3.6 mg or 6 mg once weekly in conjunction with dietary counseling.

Monitoring & Follow-up

• Monitor for gastrointestinal adverse events and weight loss progress.

Risks

• Higher incidence of nausea, vomiting, diarrhea, and constipation compared to placebo.

Patient & Prescribing Data

725 patients enrolled in the SYNCHRONIZE-1 trial.

Weight loss of at least 15% was achieved by 36% and 46% of patients on 3.6 mg and 6.0 mg, respectively.

Clinical Best Practices

• Consider patient eligibility carefully, excluding those with diabetes and uncontrolled hypertension.
• Provide counseling on a reduced-calorie diet and physical activity alongside treatment.

Related Resources & Content

• The New England Journal of Medicine